Management of Antiphospholipid Syndrome in Pregnancy

Diagnosis and Treatment

The American College of Rheumatology recommends confirming persistence of anticardiolipin antibodies with repeat testing at least 12 weeks apart, as transient positivity does not confer the same risk 2
The American Heart Association suggests assessing for triple positivity (lupus anticoagulant, anticardiolipin, and anti-β2-glycoprotein I antibodies), which indicates highest thrombotic risk 3, 2
The American College of Obstetricians and Gynecologists states that determining if clinical criteria for APS are met is crucial, including either thrombotic events OR pregnancy complications (≥3 consecutive losses <10 weeks, fetal loss ≥10 weeks, or delivery <34 weeks due to preeclampsia/growth restriction) 1, 2

For patients with obstetric APS without thrombotic events, the American College of Rheumatology recommends anticoagulation only during future pregnancies, not as life-long therapy 1, 2
The American Heart Association suggests that if the patient has experienced any thrombotic event (arterial or venous), then life-long warfarin with target INR 2.0-3.0 is recommended 3, 2, 4
The Antiphospholipid Syndrome Foundation advises against using direct oral anticoagulants (DOACs) including rivaroxaban, especially in triple-positive patients, due to excess thrombotic events 3, 2, 4

The American College of Cardiology recommends regular INR monitoring targeting 2.0-3.0 for patients on warfarin, with reassessment of risk-benefit ratio at regular intervals 2, 4
The American Society of Hematology suggests that lupus anticoagulant may interfere with INR determination—consider anti-Xa monitoring or alternative approaches if INR results are unreliable 2